Israel Looks To Nurture New Leaders For Burgeoning Biotech Sector

Israeli Industry And Investment Leaders Discuss Market Development

While Israel has not wanted for early-stage scientific excellence, leading lights in the country's biotech space are working to create an ecosystem where clinical, regulatory and managerial expertise can develop.

Israel's life sciences sector is celebrated for its academic excellence and extensive basic R&D coming out of the likes of world-renowned establishments such as the Weizmann Institute and the Hebrew University of Jerusalem. There has historically been a lack of homegrown leadership to establish companies that can bridge the gap between discovery and getting products into late-stage trials, but this it is changing.

Someone well-equipped to see how the sector is developing and how companies are being created is Anat Naschitz, a managing...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Growth

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

How To Decarbonize Pharma R&D

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.

IV-Growth (Free-1): Jump-Start Your Exercise With This Mindset Reset

 
• By 

A positive mindset can boost exercise motivation. Learn how mental shifts help you start—and stick with—a healthier fitness routine.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.